ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

INVA Innoviva Inc

15.125
0.135 (0.90%)
Last Updated: 13:16:05
Delayed by 15 minutes

Period:

Draw Mode:

Volume 70,114
Bid Price 15.12
Ask Price 15.13
News -
Day High 15.135

Low
11.3701

52 Week Range

High
16.865

Day Low 14.98
Company Name Stock Ticker Symbol Market Type
Innoviva Inc INVA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.135 0.90% 15.125 13:16:05
Open Price Low Price High Price Close Price Prev Close
15.01 14.98 15.135 14.99
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,286 70,114 $ 15.08 $ 1,057,533 - 11.3701 - 16.865
Last Trade Time Type Quantity Stock Price Currency
13:17:17 1 $ 15.125 USD

Innoviva Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
954.1M 63.23M - 310.46M 179.72M 2.84 5.31
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Innoviva News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No INVA Message Board. Create One! See More Posts on INVA Message Board See More Message Board Posts

Historical INVA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.6915.34514.6915.06818,5210.4352.96%
1 Month15.3015.34514.3314.82650,610-0.175-1.14%
3 Months16.2016.6614.3315.10724,044-1.08-6.64%
6 Months12.6816.86512.2215.03724,6492.4519.28%
1 Year11.6316.86511.370114.06678,3373.5030.05%
3 Years11.6820.705610.6414.80753,2713.4529.49%
5 Years13.6720.70567.5813.94716,3701.4610.64%

Innoviva Description

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Your Recent History

Delayed Upgrade Clock